Deregulation of energetic metabolism in the clear cell renal cell carcinoma: A multiple pathway analysis based on microarray profiling

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 287-295

  Soltysova, Andrea ^a,b   Breza, Jan ^c   Takacova, Martina ^f   Feruszova, Jana ^a   Hudecova, Sona ^a   Novotna, Barbora ^d   Rozborilova, Eva ^e   Pastorekova, Silvia ^f   Kadasi, Ludevit ^a,b   Krizanova, Olga ^a,f  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

^c UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e University Hospital in Martin   (Slovakia)

^f INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Carbonic anhydrase IX; Clear cell renal cell carcinoma; Glucose transporters; Hexokinase II; Lactate dehydrogenase A

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE II; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; MULTIENZYME COMPLEX; TUMOR ANTIGEN;

ADULT; ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPHOMA; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; ONCOCYTOMA; OXIDATIVE PHOSPHORYLATION; PH; PRIORITY JOURNAL; RESPIRATORY CHAIN; UPREGULATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; PROCEDURES;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEXOKINASE; HUMANS; KIDNEY NEOPLASMS; LACTATE DEHYDROGENASES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84931087579     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3014     Document Type: Article

References (46)

1. Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003.
2. Weiss RH and Lin PY: Kidney cancer: Identification of novel targets for therapy. Kidney Int 69: 224-232, 2006.
3. Bonassi S and Neri M: Genetic biomarkers in human population studies. In: Handbook of Genomic Medicine. Willard HF and Ginsburg GS (eds). Elsevier, 2008.
4. Beck SD, Patel MI, Snyder M.E., Kattan MW, Motzer RJ, Reuter VE and Russo P: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11: 71-77, 2004
5. Warburg O: On respiratory impairment in cancer cells. Science 124 269-270, 1956.
6. Matsumoto S, Hyodo F, Subramanian S., Devasahayam N, Munasinghe J, Hyodo E., Gadisetti C, Cook JA, Mitchell JB and Krishna MC: Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest 118: 1965-1973, 2008.
7. Vaupel P: Metabolic microenvironment of tumor cells: A key factor in malignant progression. Exp Oncol 32: 125-127, 2010.
8. Wenger RH, Stiehl DP and Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: rel2, 2005
9. Trayhurn P, Wang B and Wood IS: Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem, 114 267-276, 2008
10. Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B and Linehan WM: Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20: 207-216, 1993.
11. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires M.M., Linhart D., Worrell RA, Moch H, Rubin MA, et al.: Patterns of gene expression and copy-number alterations in Von Hippel-Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69: 4674-4681, 2009.
12. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M and de Bruine AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138, 2010.
13. Pinthus JH, Whelan KF, Gallino D, Lu JP and Rothschild N: Metabolic features of clear-cell renal cell carcinoma: Mechanisms and clinical implications. Can Urol Assoc J 5: 274-282, 2011.
14. Wykoff CC, Beasley NJ, Watson P.H., Turner KJ, Pastorek J, Sibtain A, Wilson G.D., Turley H., Talks KL, Maxwell PH, et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083, 2000.
15. Bui MH, Seligson D, Han K.R., Pantuck AJ, Dorey FJ, Huang Y, Horvath S., Leibovich BC, Chopra S, Liao SY, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9: 802-811, 2003.
16. Takacova M, Bartosova M, Skvarkova L., Zatovicova M, Vidlickova I, Csaderova L., Barathova M, Breza J Jr, Bujdak P, Pastorek J, et al.: Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett 5: 191-197, 2013.
17. Sedlakova O, Svastova E, Takacova M., Kopacek J, Pastorek J and Pastorekova S: Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol 4: 400, 2014
18. Ditte P, Dequiedt F, Svastova E., Hulikova A, Ohradanova-Repic A, Zatovicova M, Csaderova L., Kopacek J, Supuran CT, Pastorekova S, et al.: Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res 71: 7558-7567, 2011.
19. Svastova E, Witarski W, Csaderova L., Kosik I, Skvarkova L, Hulikova A., Zatovicova M, Barathova M, Kopacek J, Pastorek J, et al.: Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem 287: 3392-3402, 2012.
20. Gorbatenko A, Olesen CW, Boedtkjer E and Pedersen SF: Regulation and roles of bicarbonate transporters in cancer. Front Physiol: 16 April. 2014 doi: 10.3389/fphys.201400130.
21. + exchange activities in renal carcinoma cells. Physiol Genomics 5: 119-128, 2001.
22. Halestrap AP: The SLC16 gene family: structure, role and regulation in health and disease. Mol Aspects Med 34 337-349, 2013.
23. Doyen J, Trastour C, Ettore F., Peyrottes I, Toussant N, Gal J., Ile K, Roux D, Parks SK, Ferrero JM, et al.: Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun 451: 54-61, 2014
24. Pértega-Gomes N., Vizcaino JR, Attig J, Jurmeister S, Lopes C and Baltazar F: A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 14 352, 2014
25. Józwiak P, Krzeslak A, Pomorski L and Lipinska A: Expression of hypoxia-related glucose transporters GLUTI and GLUT3 in benign, malignant and non-neoplastic thyroid lesions. Mol Med Rep 6: 601-606, 2012.
26. Brown RS, Goodman TM, Zasadny K.R., Greenson JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29: 443-453, 2002.
27. Mori Y, Tsukinoki K, Yasuda M., Miyazawa M, Kaneko A and Watanabe Y Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol 43: 563-569, 2007
28. Flavahan WA, Wu Q, Hitomi M., Rahim N, Kim Y, Sloan A.E., Weil RJ, Nakano I, Sarkaria JN, Stringer BW, et al.: Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 16: 1373-1382, 2013.
29. Hu JW, Sun P, Zhang D.X., Xiong WJ and Mi J: Hexokinase 2 regulates Gl/S checkpoint through CDK2 in cancer-associated fibroblasts. Cell Signal 26: 2210-2216, 2014
30. Feliciano A, Castellvi J, Artero-Castro A, Leal J.A., Romagosa C., Hernández-Losa J, Peg V, Fabra A, Vidal F, Kondoh HC, et al.: miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-a, CCNJ, and MEGF9 PLoS One 8: e76247, 2013.
31. Patra KC, Wang Q, Bhaskar P.T., Miller L., Wang Z, Wheaton W, Chandel N., Laakso M, Muller WJ, Allen EL, et al.: Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24 213-228, 2013.
32. Suh DH, Kim MA, Kim H, Kim M.K., Kim HS, Chung HH, Kim YB and Song YS: Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med 14 345-353, 2014
33. Moon JS, Kim HE, Koh E, Park S.H., Jin WJ, Park BW, Park SW and Kim KS: Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem 286: 23808-23816, 2011.
34. Li B, Qiu B, Lee D.S., Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade T.P., Keith B., Nissim I, et al.: Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature 13: 251-255, 2014
35. Girgis H, Masui O, White N.M., Scorilas A., Rotondo F, Seivwright A, Gabril M., Filter ER, Girgis AH, Bjarnason GA, et al.: Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer 13: 101, 2014
36. Xie H, Hanai J, Ren J.G., Kats L., Burgess K, Bhargava P, Signoretti S., Billiard J, Duffy KJ, Grant A, et al.: Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 19: 795-809, 2014
37. Schell JC and Rutter J: The long and winding road to the mitochondrial pyruvate carrier. Cancer Metab 1: 6, 2013.
38. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R., Kögler C, Ratschek M, Schmeller N, Sperl W and Kofier B: Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 14 2270-2275, 2008.
39. Yusenko MV, Ruppert T and Kovacs G: Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci 6: 213-224, 2010.
40. Simonnet H, Alazard N, Pfeiffer K., Gallou C, Béroud C, Demont J., Bouvier R, Schägger H and Godinot C: Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23: 759-768, 2002.
41. Choueiri TK, Cheng S, Qu A.Q., Pastorek J., Atkins MB and Signoretti S: Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 31: 1788-1793, 2013.
42. Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC and Demaine AG: Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet 163: 151-155, 2005
43. White EA, Kenny HA and Lengyel E: Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev 79-80: 184-192, 2014
44. Fu L, Wang G, Shevchuk M.M., Nanus DM and Gudas LJ: Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res 71: 6848-6856, 2011.
45. Leibovich BC, Sheinin Y, Lohse C.M., Thompson RH, Cheville JC, Zavada J and Kwon ED: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25: 4757-4764, 2007
46. Zhang BY, Thompson RH, Lohse C.M., Dronca RS, Cheville JC, Kwon ED and Leibovich BC: Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int 111: 1046-1053, 2013.